TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04161872
Drug: Uricemin
Normalized name: oxybutynin chloride Oral Tablet [Urimin]
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uricemin is a nutraceutical containing quercetin, rutin, bromelain and L-carnosine
Study: NCT01607294
Drug: ETC-1002
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ETC-1002 Daily for 4 weeks
Study: NCT04100590
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked active cannabis (7% THC) vs. placebo inactive cannabis (0% THC)
Study: NCT02247232
Drug: Z-100
Normalized name: ANZ-100
DrugBank: ANZ-100 (DB05967)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03341234
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 ml %0,25 bupivacaine
Study: NCT03341234
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 ml saline subcutaneously
Study: NCT00329394
Drug: ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Evaluate the analgesic effectiveness of the systemic ketamine on the control of pain in the alcohol-dependent patient
Study: NCT00081328
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: capsule, 1000 mg bid
Study: NCT01260584
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One 10 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
Study: NCT01260584
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One 75 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
Study: NCT00176761
Drug: Interleukin-2 (IL-2)
Normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02625922
Drug: Serelaxin
Normalized name: serelaxin
DrugBank: Serelaxin (DB05794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen
Study: NCT00081328
Drug: Rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsule, 4 mg bid
Study: NCT01527500
Drug: LFG316 Lower dose
Normalized name: Calendula Flower
DrugBank: Calendula officinalis flower (DB14263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LFG316 5 mg/50 μL solution for IVT Injection
Study: NCT00652496
Drug: Bimatoprost 0.01% ophthalmic solution
Normalized name: Bimatoprost 0.01% Ophthalmic Solution
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
Study: NCT00652496
Drug: Bimatoprost 0.015% formulation 1 ophthalmic solution
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
Study: NCT00652496
Drug: Bimatoprost 0.015% formulation 2 ophthalmic solution
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
Study: NCT03151213
Drug: Pregabalin 150mg
Normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 150mg before RFA of liver cancer
Study: NCT00652496
Drug: Bimatoprost 0.02% ophthalmic solution
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
Study: NCT00652496
Drug: Bimatoprost 0.03% ophthalmic solution
Normalized name: Bimatoprost 0.03% Ophthalmic Solution
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost 0.03% ophthalmic solution, one drop in one eye, once daily in the morning for 4 consecutive days, the other eye received one drop of any of the 4 study drugs
Study: NCT00187122
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See Detailed Description section for description of treatment plan.
Study: NCT00187122
Drug: Daunomycin
Normalized name: Daunomycin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: See Detailed Description section for description of treatment plan.
Study: NCT00187122
Drug: L-Asparaginase
Normalized name: L-asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Detailed Description section for description of treatment plan.
Study: NCT00187122
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: See Detailed Description section for description of treatment plan.
Study: NCT00187122
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: See Detailed Description section for description of treatment plan.
Study: NCT00187122
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See Detailed Description section for description of treatment plan.
Study: NCT00187122
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: See Detailed Description section for description of treatment plan.
Study: NCT01078376
Drug: Azilsartan medoxomil (TAK-491)
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil 80 mg, tablets, orally, one day only
Study: NCT01078376
Drug: Azilsartan medoxomil (TAK-491)
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
Study: NCT01078376
Drug: Azilsartan medoxomil (TAK-491)
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
Study: NCT02843698
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine infusion was previously reported to improve oxygenation and lung dynamics in patients with obstructive lung diseases. In our study we are going to investigate its effect on oxygenation and lung dynamics in restrictive lung disease
Study: NCT01648699
Drug: Osmotic Release Oral System (OROS) hydromorphone
Normalized name: hydromorphone Extended Release Oral Capsule
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
Study: NCT01642771
Drug: 5-Fu/epirubicin/CTX following Docetaxel
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycle 1-3: Docetaxel i.v. 75mg/m2 (One cycle = 21 days); Cycle 4-6: Fluorouracil i.v. 500 mg/m2, Epirubicin i.v. 75 mg/m2, Cyclophosphamide i.v. 500 mg/m2 (One cycle = 21 days)
Study: NCT03023878
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Blinatumomab monotherapy was supplied in single-use sterile glass injection vials and administered as an IV infusion.
Study: NCT03023878
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 20 mg IV: within 1 hour prior to start of treatment in each treatment cycle, and within 1 hour prior to dose-step (increase).
Study: NCT00656578
Drug: 4975
Normalized name: PF-06649751
DrugBank: Tavapadon (DB14899)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, solution
Study: NCT02910726
Drug: indocyanine green (ICG)
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02261103
Drug: Pramipexole ER tablets
Normalized name: pramipexole Extended Release Oral Tablet
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02261103
Drug: Pramipexole IR tablets
Normalized name: pramipexole Oral Tablet
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02261103
Drug: Placebo matching Pramipexole ER tablets
Normalized name: pramipexole Extended Release Oral Tablet
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02261103
Drug: Placebo matching Pramipexole IR tablets
Normalized name: placebo Oral Tablet
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05110651
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Hydroxychloroquine 200mg once daily Dose tapered if blood-hydroxychloroquine levels \> 2000ng/ml
Study: NCT00796497
Drug: ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ondansetron hydrochloride (oral solution) dosage of 0.25 mg twice a day for 6 weeks followed by 0,5 mg twice a day for 6 weeks for a total observation period of 12 weeks.
Study: NCT00794573
Drug: varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
Study: NCT00690534
Drug: Insulin Regular
Normalized name: insulin regular
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: insulin, 0.2 mU/kg/min for 3 hours
Study: NCT00690534
Drug: L-NMMA
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: variable rate for 3 hours
Study: NCT00690534
Drug: Sodium Nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: variable rate for 3 hours
Study: NCT03029689
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir 1200 mg (2 tablets x 600mg) once daily plus current ART during 48 weeks from randomization
Study: NCT00986947
Drug: IVIg and rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A maximum of four doses (each single dose being 2gm/kg) of IVIg will be administered over a four-month period, with one dose administered each month. Each single dose of 2gm/kg will be administered in two half-doses (1gm/kg each) to be given one day apart, with one day of hemodialysis on the intervening day between the two half-doses.~If a compatible kidney transplant organ offer is received, upon admission to the hospital and immediately prior to the transplant operation, patients will receive a single infusion of Rituximab (375 mg/m2 BSA).
Study: NCT02972450
Drug: Vedolizumab 300 MG [Entyvio]
Normalized name: vedolizumab 300 MG [Entyvio]
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab is administered as an intravenous infusion over 30 mins in the dominant arm. After infusion, the line should be flushed with 30mls of normal saline.
Study: NCT02094248
Drug: TPO
Normalized name: Tpoxx
DrugBank: Tecovirimat (DB12020)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: rhTPO（Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China）， 15000U/ml, s.c injection
Study: NCT02094248
Drug: control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal saline，1ml/day, s.c injection
Study: NCT02637466
Drug: Vortioxetine
Normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01169571
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01294358
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine starting dose was 18mg/m(2)/24h via infusion pump on days 1-14. One cycle = 4 weeks for up to six cycles. Three to six patients enrolled per dose cohort. Patients were dosed at successive higher doses until maximum tolerated dose or up to 165 mg/m(2)/24h.
Study: NCT03356145
Drug: 12 mL paracervical block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 12 mL of lidocaine
Study: NCT03356145
Drug: 20 mL paracervical block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 20 mL of lidocaine
Study: NCT00848640
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg twice daily
Study: NCT00524693
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4mg sachets
Study: NCT01283867
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate Mofetil 500 mg tablets
Study: NCT02420938
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course.
Study: NCT02420938
Drug: Urelumab
Normalized name: Urelumab
DrugBank: Urelumab (DB12077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the 12-week course.
Study: NCT04052360
Drug: Cenerimod
Normalized name: Cenerimod
DrugBank: Cenerimod (DB12705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 4 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
Study: NCT03705845
Drug: DeltaGold® Tocotrienol 70%
DrugBank: Tocotrienol (DB12647)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DeltaGold® Tocotrienol 70% contains 430 mg tocotrienol (90% δ-tocotrienol + 10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
Study: NCT00702234
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vaginal administration of progesterone at a dose of at least 600 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
Study: NCT00010803
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120mg twice a day
Study: NCT00098540
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT01083537
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1) Cisplatin administered at 60mg/m2 IV on Day 1, every 21 days for 2 cycles.~1. Hesketh Level 5: 5HT3 receptor antagonist IV/po 30-60 mins pre-chemo and Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; Dexamethasone 4-8mg po BID x 3 days starting 24hours post last dose of chemo; Prochlorperazine 10mg po/IV q4-6h prn, metoclopramide 10-20mg po/iv q6h prn, haloperidol 0.5-2mg po/SC q 8-12 h prn~2. Hydration: Pre-hydration 500-1000cc NS with 10Meq KCl over 2 hours; Infuse Cisplatin in 250-500cc NS over 1 hour; Post-hydration 1000cc NS + 20Meq KCl (+/- 2g MgSO4) over 1 hour
Study: NCT01083537
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2) Paclitaxel administered 80mg/m2 IV on Days 1, 8 and 15, every 21 days for 2 cycles.~1. Suggested prophylaxis for paclitaxel-associated hypersensitivity reactions: Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; diphenydramine 25-50mg IV 30-60 minutes pre-chemo, ranitidine 50mg IV 30-60 minutes pre-chemo~2. Hesketh Level 2: Prochlorperazine 10mg po/IV q4-6h prn~3. Hydration: Infuse Paclitaxel in 250cc NS over 1 hour
Study: NCT02684942
Drug: Meperidine
Normalized name: Meperidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
Study: NCT02916745
Drug: Porfimer sodium
Normalized name: Porfimer Sodium
DrugBank: Porfimer sodium (DB00707)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). A light dose of 200 J/cm of diffuser length will be delivered.
Study: NCT02335242
Drug: Sildenafil 20 mg tablets
Normalized name: sildenafil 20 MG
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00690950
Drug: Dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg capsule, taken once daily for 12 months
Study: NCT00089635
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered by intravenous infusion
Study: NCT00984347
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For low risk group (women at deliveries 1-5):~IV oxytocin 10IU/1000ml standard sol. starting at 2MU/MIN and augmenting 2MU every 20 min.~For high risk group (grandmultiparas \[6th delivery and up\] or women with a previous cesarean section)~IV oxytocin 5IU/1000ml standard sol. starting at 1MU/MIN augmenting 1MU every 20 MIN - in accordance with the department's protocol
Study: NCT03353948
Drug: MET
Normalized name: Met
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the MET group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os for 12 weeks. After 1 month IVF was done.
Study: NCT03353948
Drug: COMBI
Normalized name: Combivir
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the COMBI group the initial dose of MET was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg BID. Liraglutide 1.2 mg QD s.c. was added after first two weeks of monotherapy with MET. After 1 month IVF was done.
Study: NCT02135588
Drug: Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00266162
Drug: Bosentan administration
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01956864
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses of vitamin D will be increased from a baseline dose to the maximum tolerated dose. There could therefore be up to 5 possible doses of Vitamin D. Once the maximum tolerated dose of vitamin D has been determined, patients will follow a regimen on that dose for 6 months.
Study: NCT02453659
Drug: Transdermal Nicotine Patch
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02007278
Drug: vildagliptin and metformin (combination)
Normalized name: metformin and linagliptin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: vildagliptin and metformin combination therapy as 50mg/850mg bid or 50mg/1000mg bid
Study: NCT02007278
Drug: glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02007278
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00365183
Drug: Motexafin gadolinium and pemetrexed
Normalized name: gadolinium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 dose of MGd 15 mg/kg and pemetrexed 500 mg/m2 once during the first week of every 3-week treatment cycle for a maximum of 12 cycles
Study: NCT03594045
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban is an anticoagulant that works by inhibiting the coagulation factor, Factor Xa.
Study: NCT00795769
Drug: ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03129295
Drug: MPC-SHRC
Normalized name: GIVI-MPC
DrugBank: GIVI-MPC (DB17905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet four times a day for 3 days
Study: NCT00145496
Drug: Asenapine
Normalized name: Asenapine
DrugBank: Asenapine (DB06216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-10 mg sublingually twice daily for up to 26 weeks
Study: NCT00145496
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-20 mg by mouth once daily for up to 26 weeks
Study: NCT03157414
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin tablets enclosed with red capsules (Capsugel AAEL) by Kragerø Tablettproduksjon AS for blinding purpose
Study: NCT03152474
Drug: Vitamin A 100,000 IU
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosed Intramuscular once daily
Study: NCT04652050
Drug: Tolsura
Normalized name: Tolsura
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients fulfilling the inclusion criteria (see above) and placed on Tolsura for prophylaxis, and signed informed consent to participate in this study will be part of the study.